Incyte Corporation develops and sells drugs treating cancer and inflammatory diseases, with its Jakafi treatment for certain blood cancers and bone marrow disorders representing its most significant commercial product. The company both develops its own drugs internally and has licensing partnerships with other pharmaceutical companies, sharing in royalties and milestone payments from drugs based on its research that are marketed by partner companies in certain regions or indications. As a biopharmaceutical company focused on oncology and inflammation, Incyte's growth depends heavily on both the continued commercial performance of its marketed drugs and its ability to advance new drug candidates through its research pipeline into approved treatments. The company's revenue and profitability can be affected by patent expirations on its key products and competitive pressure from other treatments targeting the same diseases as its established drug franchise.